The Occupier Solutions Team was chosen to represent a biopharmaceutical company headquartered in France for site selection of an East Coast facility to serve the Americas. The company focusedon developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART).
Challenges
Client sought North American presence with closest proximity to Europe.
The inventory of available space was extremely tight in 2019.
Results
2500 Sumner Boulevard in Raleigh was selected as a culmination of an extensive search – reflective of the current availability of suitable building inventory to support commercial manufacturing of UCART therapies.
The Occupier Solutions Team also assisted with connections and acquisitions in local and state economic development incentives.
